Multiple sclerosis: TOWER confirms the efficacy of oral teriflunomide in MS

Nature Reviews Neurology

Volumn 10, Issue 4, 2014, Pages 183-184

  Haghikia, Aiden ^a   Gold, Ralf ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BETA1A INTERFERON; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; LEFLUNOMIDE; LIVER ENZYME; MITOXANTRONE; NATALIZUMAB; PLACEBO; TERIFLUNOMIDE;

ADD ON THERAPY; ANTIINFLAMMATORY ACTIVITY; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; INFECTION; LIVER FAILURE; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SHORT SURVEY; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

CROTONATES; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TOLUIDINES;

EID: 84897980673     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2014.42     Document Type: Short Survey

References (10)

1. Confavreux, C. et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 13, 247-256 (2014
2. O'Connor, P. et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med. 365, 1293-1303 (2011
3. O'Connor, P. W. et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66, 894-900 (2006
4. Gold, R. & Wolinsky, J. S. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol. Scand. 124, 75-84 (2011
5. Bar-Or, A. et al. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology 81, 552-558 (2013
6. Vermersch, P. et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: A randomised, controlled phase 3 trial. Mult. Scler. http://dx.doi.org/10.1177/1352458513507821
7. Freedman, M. S. et al. Teriflunomide added to interferon β in relapsing multiple sclerosis: A randomized phase II trial. Neurology 78, 1877-1885 (2012
8. Korn, T., Toyka, K., Hartung, H. P. & Jung, S. Suppression of experimental autoimmune neuritis by leflunomide. Brain 124, 1791-1802 (2001
9. Fuentealba, R. A., Marasa, J., Diamond, M. I., Piwnica-Worms, D. & Weihl, C. C. An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors. Hum. Mol. Genet. 21, 664-680 (2012
10. Haghikia, A., Hohlfeld, R., Gold, R. & Fugger, L. Therapies for multiple sclerosis: Translational achievements and outstanding needs. Trends Mol. Med. 19, 309-319 (2013.